Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study
- 15 December 2016
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 45 (4), 501-509
- https://doi.org/10.1111/apt.13895
Abstract
Nucleoside analogue prescription was associated with a reduction of overall liver cancer incidence in a CHB-prevalent region. The lack of association among individuals of ≥65 years was consistent with the low nucleoside analogue prescription volume in elderly patients, mitigating the impact of CHB treatment on liver cancer.Keywords
Funding Information
- University of Hong Kong
This publication has 26 references indexed in Scilit:
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort StudyGastroenterology, 2014
- Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosisHepatology, 2013
- Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionHepatology, 2012
- EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infectionJournal of Hepatology, 2012
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort studyGut, 2011
- Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis BHepatology, 2010
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004
- HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUSThe Lancet, 1981